Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Chemotherapy delays pancreatic cancer recurrence

  • Comment
The use of the drug gemcitabine for chemotherapy significantly delays the recurrence of pancreatic cancer compared to no chemotherapy, a study has shown.

The use of the drug gemcitabine for chemotherapy significantly delays the recurrence of pancreatic cancer compared to no chemotherapy, a study has shown.

Research conducted in a sample of 386 patients with pancreatic cancer found patients were less likely to have recurrent cancer after treatment with gemcitabine.

In the 179 patients treated with the drug, 74.3% had recurrent cancer. Among the 175 patients in the control group, who did not receive the drug, 92% had recurrent cancer.

Estimated disease-free survival at three and five years was 23.5% and 16.5% in the gemcitabine group and 7.5% and 5.5% in the control group respectively.

Journal of the American Medical Association (2007) 297: 267-277

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.